Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Adderall XR Prescribers (US)

Articles with lock require a subscription to GLG News | Request a free trial
May 12, 2008
Will Strattera be around in 3 years?
Analysis of: FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents | newsroom.lilly.com
Author: GLG Expert Contributor
My personal prediction is that this product will NOT be on the market in 3-5 years.  My clinical experience never approached that which the research would suggest.  I suspect that the "research" that was done on this product is frought with company incentives.
May 12, 2008
Neuronal nicotinic receptor agonists potential breakthrough for ADHD research
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: GLG Expert Contributor
1. Effective treatment for ADHD 2. Well tolerated with few side effects 3. Help with smoking, a big problem in ADHD patients important 4. Advantage in not being Schedule II may be helpful
May 12, 2008
Important New Data for Children and Adolescents
Analysis of: FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents | newsroom.lilly.com
Author: GLG Expert Contributor
1. Important new finding given safety concerns raised about this and other treatmetns 2. Nice to have data back up what has long been done clinically 3. Stimulants still first line and lack of active comparator trial
Louis SanfilippoApril 28, 2008
Glaxo Decision Moves Drug Development Forward Again
Analysis of: Federal Court Sides With GlaxoSmithKline, Strikes Down Rules Issued by Patent Office | biz.yahoo.com
Author: Louis Sanfilippo, President, LCS Group, LLC
The USPTO’s proposed rule changes, struck down in this important Glaxo federal court decision, would have added significant burdens to pharmaceutical companies in developing their IP portfolios and ultimately their drug treatments.   The proposed changes were seemingly motivated to make the...
Louis SanfilippoApril 24, 2008
Corcept Therapeutics Takes Yet Another Shot at Psychotic Depression
Analysis of: Corcept Therapeutics Announces Commencement Of Next Phase 3 Study With CORLUX(R) For The Treatment Of Psychotic Depression | www.biospace.com
Author: Louis Sanfilippo, President, LCS Group, LLC
Corcept Therapeutics is at it again with yet another clinical trial for its lead candidate mifeprisotone (Corlux), a GR-II (glucocorticoid) receptor antagonist, hoping to show efficacy on the psychotic features of psychotic major depression (PMD).   Corlux clearly offers a potentially novel...
Daniel WynnApril 24, 2008
COPAXONE from the START of MS
Analysis of: Teva Seeks Approval for the Extension of its Indication to Include the Treatment of Patients with a First Clinical Event Suggestive of MS | www.pipelinereview.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Copaxone has become the leading treatment for relapsing remitting MS in the US.  The results of the PRECISE trial will likely add to TEVA's sales momentum and boost sales further.
Louis SanfilippoApril 17, 2008
Another Casualty in Antidepressant Development
Analysis of: EPIX Pharmaceuticals Announces Discontinuation of PRX-00023 Clinical Development Program | biz.yahoo.com
Author: Louis Sanfilippo, President, LCS Group, LLC
The development of a new generation of serortinin 5HT1a agonists for major depression and anxiety disorders has met yet another failure, now from EPIX Pharmaceuticals’  PRX-00023.  Gepirone ER (GlaxoSmithKline), another 5HT1a partial agonist, suffered the same fate last November when...
April 9, 2008
ROTARIX(R) Rotavirus Vaccine Will Give Pediatricians Another Vaccination Option
Analysis of: FDA Approves ROTARIX(R) Rotavirus Vaccine | www.pipelinereview.com
Author: GLG Expert Contributor
Clinical trials have shown very similar efficacy and safety with both GSK's Rotarix and Merck's Rotateq.  With only two doses needed for Rotarix, pediatricians may opt for a simpler schedule.  Financial consideration will likely play the largest role in adopting the new vaccine.
April 8, 2008
Current trends with Venture Capital Funds and IPO's
Analysis of: Venture Activity Hit by U.S. Slowdown | online.wsj.com
Author: GLG Expert Contributor
As a partner @ a VC fund I  see this trend impacting how potential portfolio companies are evaluated.  Companies that will have a future acquisition, as an liquidity event, will have a higher probability of being funded.  Investment decisons are also being influenced by the potential...
April 8, 2008
Eli Lilly is on the right track with gamma secretase inhibiors
Analysis of: Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease | www.fiercebiotech.com
Author: GLG Expert Contributor
Disease modification is the desired direction for drugs to treat Alzheimer's and gamma secretase inhibitors have really just begun to be studied.  The field is very promising.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 215

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747